CloudMD Software & Services (CSE: DOC) this morning announced that it has entered into an agreement that will see its Livecare telemedicine application expanded into the United States market. The expansion comes via a value added reseller agreement entered into with that of IDYA4 Corp.
The agreement will see IDYA4, a leader in data interoperability and integrations within public and private sectors, resell the company’s Livecare tech within the US. Notable clients of IDYA4 include the US Department of Justice, Bureau of Justice Assistance, the Department of Homeland Security, the CDC, and US Health and Human Services among others. IDYA4’s client base offers significant opportunity for Livecare, especially as these public departments search for telemedicine solutions amidst the ongoing coronavirus pandemic to limit person to person contact.
Under the agreement, IDYA4 will act as CloudMD’s US based partner, selling the platform to its client base across the country. The firm will provide distribution, infrastructure, on-boarding and IT support for Livecare across the US. CloudMD will also look to see its Livecare Carts – pre-configured telehealth carts that offer real-time diagnostic input and clinical evaluations – distributed across the US under the agreement to remote communities in search of improving quality of care for their population.
The partnership provides a significant opportunity for CloudMD to expand its client base into that of the United States. IDYA4’s extensive relationships within the corrections system, whom is currently experiencing mass outbreaks of the coronavirus, provides ample opportunity for CloudMD’s telehealth platform and further demonstrates the strength of the firms product offerings.
Sponsored · Granada Gold Mine
CloudMD Software & Services last traded at $0.87 on the CSE.
FULL DISCLOSURE: CloudMD Software & Services is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover CloudMD Software & Services on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
